等待开盘 11-18 09:30:00 美东时间
-0.020
-0.26%
今日重点评级关注:瑞银:维持Liberty Media"中性"评级,目标价从110美元升至1116美元;杰富瑞:维持伊诺维奥制药"买入"评级,目标价从3美元升至8美元
11-09 14:00
The latest update is out from Iovance Biotherapeutics ( ($IOVA) ). On November ...
11-06 07:26
华盛资讯11月6日讯,Iovance Biotherapeutics公布2026财年Q3业绩,公司Q3营收1.22亿美元,同比增长80.0%。
11-06 06:20
华盛资讯11月5日讯,Iovance Biotherapeutics公布2026财年Q3业绩,公司Q3营收1.21亿美元,同比增长80.1%,归母净利润亏损0.22亿美元,同比亏损缩窄75.6%。
11-05 22:34
华盛资讯11月5日讯,Iovance Biotherapeutics公布2026财年Q3业绩,公司Q3营收1.21亿美元,同比增长80.1%,归母净利润亏损0.22亿美元,同比亏损缩窄75.6%。
11-05 20:17
Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.09) by 37.5 percent. This is a 80 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $121.460 m...
11-05 20:09
今日重点评级关注:Rosenblatt:维持SiTime"买入"评级,目标价从750美元升至900美元;花旗:维持Madrigal Pharmaceuticals"买入"评级,目标价从725美元升至760美元
11-04 18:17
UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $7 to $8.
11-04 00:01
50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Unprecedented Efficacy in Both Refractory Undifferentiated Pleomorphic Sarcoma (UPS) and Dedifferentiated Liposarcoma (DDLPS) PHILADELPHIA ...
10-26 19:05
Iovance Biotherapeutics is advancing TIL cell therapy in solid tumor treatment, presenting new clinical data at ESMO 2026. Two oral presentations highlight deep, durable responses in frontline melanoma and soft tissue sarcomas, including undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). The company also展示Poster presentations on translational and real-world evidence, including improved survival rates with lifileu...
10-19 11:00